Veeva eTMF Revisited
Taking a Fresh Look at Risk-Based Quality Control
Every clinical trial team is being asked to accomplish more with limited resources.
Record Quality Control remains an essential part of maintaining a complete, accurate, and inspection-ready Trial Master File. But a risk-proportionate quality environment raises an important business question:
Does every Record QC activity deliver the same value?
Consider two record types, or artifacts. One directly supports evidence of participant safety or a primary endpoint. Another is administrative in nature.
Should the business process automatically direct the same level of QC effort toward both?
Every organization may answer that question differently based on its own studies, risk strategy, and operating model. But as risk-proportionate approaches become more deeply embedded in clinical trial management, it is a conversation worth having.
And Veeva eTMF already provides functionality to support it.
As clinical research and trial management evolve, there is value in periodically looking at the technology that supports it with a fresh perspective.
Not because the technology needs to change.
Because the way we use it can continue to mature.
That is the inspiration behind Veeva Clinical and Veeva Quality Cloud Revisited, a new series from Just in Time GCP exploring existing Veeva capabilities through the lens of today’s clinical research environment.
Unlocking the Potential of Risk-Based QC
Veeva eTMF includes capabilities that allow organizations to support a risk-based approach to Quality Control. Organizations are able to define record risk levels, configure sampling strategies and differentiated Record QC rules, and monitor the effectiveness of those rules over time.
Importantly, the technology doesn’t determine what constitutes risk for an organization. That remains a business and quality decision.
Veeva eTMF provides the flexibility to support those decisions, allowing organizations to align Record QC activities with their quality strategy, study needs, and business processes. The opportunity, therefore, isn’t simply about having the functionality available.
It’s about ensuring that available functionality continues to support the organization’s evolving business processes and helps the organization take full advantage of its Veeva eTMF investment.
Where Business Process Matters
Moving toward a more risk-proportionate Record QC approach requires more than technology.
Organizations need to determine what matters most within their own clinical programs.
- Which records have the greatest potential impact on human subject protection, participant safety, data integrity, or inspection readiness?
- Where does additional review provide meaningful quality value?
- Where might a sampling strategy be appropriate?
- How will risk levels be established and governed?
- What information will be used to evaluate whether the approach is working as intended?
These are business, clinical, and quality questions.
As regulatory expectations, study risks, and business operations evolve, the processes that support them may evolve too. Periodically revisiting how technology supports those processes can help organizations ensure they are taking full advantage of the technological capabilities already available to them.
That's where Just in Time GCP comes in.
Just in Time GCP brings a clear understanding of regulatory expectations, study risk, TMF processes, clinical quality oversight, and inspection readiness to help sponsors evaluate how Veeva eTMF continues to support their evolving business needs, identify opportunities to optimize functionality, and unlock more value from the technology they already have.
For Risk-Based QC, that can mean helping teams assess study and record risk, define an appropriate risk-proportionate QC strategy, establish governance and decision-making processes, and determine how existing Veeva eTMF functionality can best support that strategy in day-to-day operations.
Questions Worth Revisiting
A fresh look at Risk-Based QC might start with a few questions:
- Are we applying QC effort in proportion to the risk and criticality of the records being reviewed?
- Are we focusing greater scrutiny on record types, processes, studies, or areas with known or emerging quality risks?
- Are historical QC findings and quality trends being used to adjust the level of review over time?
- Can we demonstrate that reduced QC in lower-risk areas is supported by data and documented rationale, rather than simply by an effort to reduce workload?
- Do our processes, governance, and oversight mechanisms support a consistent and defensible risk-based QC methodology?
- Are we using the capabilities available within Veeva eTMF to operationalize and monitor the risk-based approach?
- Are we measuring whether the strategy is actually achieving its intended outcome: reliable, high-quality TMF records with review effort concentrated where it adds the greatest value?
Every organization will arrive at different answers.
Risk-Based QC is not simply a mechanism for reducing the percentage of records reviewed. It is a structured, technology-enabled approach that uses existing eTMF capabilities, quality data, and risk indicators to concentrate QC activities where they are most likely to identify, prevent, or mitigate meaningful quality risks.
A Head Start on Risk Assessment – Just in Time GCP brings an established artifact-level TMF risk assessment that can serve as a baseline for these conversations. Informed by global regulatory requirements and 20 years of experience supporting regulatory inspections, it provides a practical starting point for evaluating record risk in the context of each sponsor’s studies, quality strategy, and operating model.
Maximizing the Value of Veeva eTMF
One of the advantages of a mature enterprise platform is the depth of functionality already available to support evolving business needs.
As regulations evolve, organizations mature, and approaches to clinical quality advance, there are opportunities to revisit those capabilities with a new perspective.
For some organizations, Risk-Based Quality Control may be one of them.
Just in Time GCP works with trial sponsors to bring TMF, clinical quality, GCP, and inspection readiness expertise to these conversations, helping organizations maximize how Veeva eTMF capabilities support their evolving business processes.
Because sometimes the next opportunity isn’t about adding something new.
It's about unlocking more potential from what you already have.
That’s the thinking behind Veeva Clinical and Veeva Quality Cloud Revisited.
